SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-008888
Filing Date
2018-11-08
Accepted
2018-11-07 21:52:22
Documents
56
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20180930x10q.htm 10-Q 2035128
2 EX-31.1 tbph-20180930ex31175b684.htm EX-31.1 14947
3 EX-31.2 tbph-20180930ex3127e6dd6.htm EX-31.2 14949
4 EX-32 tbph-20180930xex32.htm EX-32 17313
  Complete submission text file 0001558370-18-008888.txt   5958131

Data Files

Seq Description Document Type Size
5 EX-101.INS tbph-20180930.xml EX-101.INS 1132728
6 EX-101.SCH tbph-20180930.xsd EX-101.SCH 38282
7 EX-101.CAL tbph-20180930_cal.xml EX-101.CAL 44388
8 EX-101.DEF tbph-20180930_def.xml EX-101.DEF 131493
9 EX-101.LAB tbph-20180930_lab.xml EX-101.LAB 332419
10 EX-101.PRE tbph-20180930_pre.xml EX-101.PRE 253019
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 181167964
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1